DAVI
DAVION HEALTHCARE PLCPrice
Daily candles with volume.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA| Oct 26, 2026 | 🔒 Fresh data, subscribers only | |
SecBot reports
3 filings · 1 press release · 0 bullish · 0 bearish · 3 neutral- NEUTRAL PRESS RELEASEOct 26, 2026
Davion Healthcare Plc acquired the IP of two medical technologies (WoundSkan smart wound dressing and Spektra lateral flow test platform) from Humaskan Ltd for $25M total consideration ($2.5M cash + ~$22.5M in shares at a fixed $13.00/share contractual value). This is Davion's first acquisition…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 6-KOct 20, 2026
Davion Healthcare Plc announced its ordinary shares are expected to commence trading on the Nasdaq…
Monitor the first trading days on Nasdaq for liquidity and price discovery. The key catalyst remains the first commercial launch of BreastCheck in H2 2026 and the company's ability to generate…
- NEUTRAL 6-KSep 15, 2026
Davion Healthcare announced the admission of a £30 million senior secured bond (10.5% coupon…
Davion Healthcare announced the admission of a £30 million senior secured bond (10.5% coupon, 5-year term) issued by its subsidiary Davion Healthcare Finance Ltd to the Vienna MTF. Proceeds will…
- NEUTRAL 20-FApr 30, 2026
Davion Healthcare Plc filed its 20-F annual report for FY2025, confirming it remains a pre-revenue…
Monitor for Nasdaq listing clearance and the NeuRX BreastCheck commercial launch in H2 2026, which is the primary revenue catalyst. The $1.5M convertible note and $2.0M term loan facility provide…
All DAVI filing & press-release reports (4)
- PRESS-RELEASE reportOct 26, 2026
- 6-K reportOct 20, 2026
- 6-K reportSep 15, 2026
- 20-F reportApr 30, 2026